Pathogenesis of atherosclerosis

Seminars in Nephrology

Volumn 16, Issue 1, 1996, Pages 12-20

  Massy, Ziad A ^a   Keane, William F ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL INTERACTION; DISEASE ASSOCIATION; HUMAN; HYPERLIPIDEMIA; INFLAMMATORY INFILTRATE; LIPOPROTEIN METABOLISM; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; OXIDATION-REDUCTION;

EID: 0030065598     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Ross R: The pathogenesis of atherosclerosis-an update. N EngI J Med 314:488-500, 1986
2. Wilson PWF: Established risk factors and coronary artery disease: The Framingham study. Am J Hypertens 7:7S-12S, 1994
3. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993
4. Stary HC, Blankenhorn DH, Chandler AB, et al: A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 85:391-405, 1992
5. Steinberg D, Parthasarthy S, Crew TE, et al: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
6. Noll G, Lüscher TF: Influence of lipoproteins on endothelial function. Thromb Res 74:S45-S54, 1994
7. Sigal E, Laughton CW, Mulkins MA: Oxidation, lipoxygenase, and atherogenesis. Ann NY Acad Sci 714:211-224, 1994
8. Daugherty A, Dunn JL, Raten DL, et al: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444, 1994
9. Änggard E: Nitric oxide: Mediator, murderer, and medicine. Lancet 343:1199-1206, 1994
10. Cushing SD, Berliner JA, Valente AJ, et al: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134-5138, 1990
11. van der Wal AC, Das PK, Tigges AJ, et al: Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 141:1427-1433,1992
12. Mitchinson MJ: The new face of atherosclerosis. Br J Clin Pract 48:149-151, 1994
13. Nachman RL: Review: Stratton Lecture. Thrombosis and atherogenesis: Molecular connections. Blood 79:18971906, 1992
14. Liu AC, Lawn RM: Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med 4:40-44, 1994
15. Nafziger AN: Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment. Drugs 48:1-8, 1994
16. Henderson AH: Endothelium in control. Br Heart J 65:116-125, 1991
17. Lerman A, Bumett JC Jr: Intact and altered endothelium in regulation of vasomotion. Circulation 86:11112-19, 1992
18. Davies PF: Vascular cell interactions with special reference to the pathogenesis of atherosclerosis. Lab Invest 55:5-24, 1986
19. Raines EW, Ross R: Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69: S30-S37, 1993
20. Pardee AB: G, events and regulation of cell proliferation. Science 246:603-608, 1989
21. Davies MG, Ramkumar V, Gettys TW, et al: The expression and function of G-proteins in experimental intimai hyperplasia. J Clin Invest 94:1680-1689, 1994
22. Irani K, Herzlinger S, Finkel T: RAS proteins regulate multiple mitogenic pathways in A10 vascular smooth muscle cells. Biochem Biophys Res Commun 202:1252-1258, 1994
23. Watanabe T, Hirata M, Yoshikawa Y, et al: Role of macrophages in atherosclerosis. Sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab Invest 53:80-90, 1985
24. Faruqi RM, DiCorleto PE: Mechanisms of monocyte recruitment and accumulation. Br Heart J 69:SI9-S29, 1993
25. Butcher EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 67:1033-1036, 1991
26. Valente AJ, Rozek MM, Sprague EA, et al: Mechanisms in intimai monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 86:111-20111-25, 1992
27. Ruggeri ZM: von Willebrand factor as a target for antithrombotic intervention. Circulation 86:111-26-111-29, 1992
28. Loscalzo J: The relation between atherosclerosis and thrombosis. Circulation 86:111-95-111-99, 1992
29. Libby P, Li H: Vascular cell adhesion molecule-1 and smooth muscle cell activation during atherogenesis. J Clin Invest 92:538-539, 1993
30. Yoshimura T, Leonard EJ: Human monocyte chemoattractant protein-1: Structure and function. Cytokines4: 131-152, 1992
31. Navab M, Imes SS, Hama SY, et al: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88:2039-2046, 1991
32. Collins T: Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 68:499-508, 1993
33. Parhami F, Fang 2T, Fogelman AM, et al: Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 92:471-478, 1993
34. Lawrence R, Chang L, Seibenlist U, et al: Vascular smooth muscle cells express a constitutive NF-κB-like activity. J Biol Chem 46:28913-28918, 1994
35. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252-5256, 1991
36. Nelken NA, Coughlin SR, Gordon D, et al: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88:1121-1127, 1991
37. Ikeda U, Ikeda M, Seino Y, et al: Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines. Atherosclerosis 104:61-68, 1993
38. Jiang Y, Beller DI, Frendl G, et al: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148:2423-2428, 1992
39. Clinton SK, Underwood R, Hayes L, et al: Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 140: 301-316, 1992
40. Rosenfeld ME, Ylä-Herttuala S, Lipton BA, et al: Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol 140:291-300, 1992
41. Clinton SK, Libby P: Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 116:1292-1300, 1992
42. Barath P, Fishbein MC, Cao J, et al: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 65:297-302, 1990
43. Pauletto P, Sarzani R, Rappelli A, et al: Differentiation and growth of vascular smooth muscle cells in experimental hypertension. Am J Hypertens 7:661-674, 1994
44. Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88: 3739-3743, 1992
45. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
46. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
47. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777, 1989
48. Masaki T: Endothelin in vascular biology. Ann NY Acad Sci 714:101-108, 1994
49. Hirota S, Imakita M, Kohri K, et al: Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 143:1003-1008, 1993
50. Shanahan CM, Cary NRB, Metcalfe JC, et al: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393-2402, 1994
51. Durrington PN: How HDL protects against atheroma. Lancet 342:1315-1316, 1993
52. Hansson GK, Jonasson L, Holm J, et al: Gamma-interferon regulates vascular smooth muscle proliferation and la antigen expression in vivo and in vitro. Circ Res 63:712-719, 1988
53. Sage EH, Bornstein P: Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 266:14831-14834, 1991
54. Chu CT, Pizzo SV: α2-Macroglobulin, complement, and biologic defense: Antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest 71:792-812, 1994
55. Chobanian AV: Can antihypertensive drugs reduce atherosclerosis and its clinical complications. Am J Hypertens 7:119S-125S, 1994
56. Brown BG, Zhao X, Sacco DE, et al: Atherosclerosis regression plaque disruption, and cardiovascular events: A rationale for lipid lowering in coronary artery disease. Annu Rev Med 44:365-376, 1993
57. Levine GN, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 332:512-521, 1995
58. Sasahara M, Raines EW, Chait A, et al: Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 94: 155-164, 1994
59. Anderson TJ, Meredith IT, Yeung AC, et al: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995
60. Fruebis J, Steinberg D, Dresel HA, et al: A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 94:392-398, 1994
61. Corsini A, Raiteri M, Soma M, et al: Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. PharmacolRes23:l73-180, 1991
62. O'Donnell MP, Kasiske BL, Kim Y, et al: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91: 83-87, 1993
63. Furberg CD, Adams HP, Applegate WB, et al: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90:1679-1687, 1994
64. Weintraub WS, Boccuzzi SJ, Klein L, et al: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 331: 1331-1337, 1994
65. Kobashigawa JA, Carr JG, Moriguchi JD, et al: Pravastatin lowers cholesterol and appears to decrease transplant coronary artery disease. A randomized trial. Circulation 90: 1-94 1994 (abstr)